191 related articles for article (PubMed ID: 15467584)
1. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
Barbour LA; Oja JL; Schultz LK
Am J Obstet Gynecol; 2004 Sep; 191(3):1024-9. PubMed ID: 15467584
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
Jacobsen AF; Qvigstad E; Sandset PM
BJOG; 2003 Feb; 110(2):139-44. PubMed ID: 12618157
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
4. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin.
Abildgaard U; Sandset PM; Hammerstrøm J; Gjestvang FT; Tveit A
Thromb Res; 2009 Jul; 124(3):262-7. PubMed ID: 19162303
[TBL] [Abstract][Full Text] [Related]
5. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
[TBL] [Abstract][Full Text] [Related]
6. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
7. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy.
Ensom MH; Stephenson MD
J Soc Gynecol Investig; 2004 Sep; 11(6):377-83. PubMed ID: 15350250
[TBL] [Abstract][Full Text] [Related]
9. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
10. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
11. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
[TBL] [Abstract][Full Text] [Related]
12. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
Clark NP; Delate T; Cleary SJ; Witt DM
Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
Douketis JD; Kinnon K; Crowther MA
Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels.
Gyamfi C; Cohen R; Desancho MT; Gaddipati S
J Matern Fetal Neonatal Med; 2005 Nov; 18(5):329-31. PubMed ID: 16390793
[TBL] [Abstract][Full Text] [Related]
16. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.
Hunt BJ; Doughty HA; Majumdar G; Copplestone A; Kerslake S; Buchanan N; Hughes G; Khamashta M
Thromb Haemost; 1997 Jan; 77(1):39-43. PubMed ID: 9031446
[TBL] [Abstract][Full Text] [Related]
17. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
Wilson SJ; Wilbur K; Burton E; Anderson DR
Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
[TBL] [Abstract][Full Text] [Related]
18. Use of low molecular weight heparin in pregnant women with mechanical heart valves.
Yinon Y; Siu SC; Warshafsky C; Maxwell C; McLeod A; Colman JM; Sermer M; Silversides CK
Am J Cardiol; 2009 Nov; 104(9):1259-63. PubMed ID: 19840573
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels?
Goland S; Schwartzenberg S; Fan J; Kozak N; Khatri N; Elkayam U
J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):451-6. PubMed ID: 24607762
[TBL] [Abstract][Full Text] [Related]
20. Obstetric outcome with low molecular weight heparin therapy during pregnancy.
Donnelly J; Byrne J; Murphy K; McAuliffe F
Ir Med J; 2012 Jan; 105(1):27-9. PubMed ID: 22397211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
